Drug Trial Radar · NCT00672724
Efficacy of Ramelteon in Adults With Chronic Insomnia
Last checked: Nov 20, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,081
Actual
Start
Feb 2005
Primary completion
Aug 2005
Study completion Aug 2005
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 6, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate subjectively reported treatment effects of ramelteon, once daily (QD), in adults with chronic insomnia.
Conditions
- Chronic Insomnia
Interventions
RamelteonDrug
Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
PlaceboDrug
Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Subjective Sleep Latency determined through subject responses on morning questionnaire.Time frame: Day 8
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Cerritos, California
Site not named
La Jolla, California
Site not named
La Mesa, California
Site not named
Oakland, California
Site not named
Denver, Colorado
Site not named
Bay Harbor Island, Florida
Site not named
Brandon, Florida
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Myers, Florida
Site not named
Hollywood, Florida
Site not named
Miami, Florida
Site not named
Pembroke Pines, Florida
Site not named
Pinellas Park, Florida
Site not named
Vero Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Austell, Georgia
Site not named
Macon, Georgia
Site not named
Boise, Idaho
Site not named
Northbrook, Illinois
Site not named
Prairie Village, Kansas
Site not named
Wichita, Kansas
Site not named
Louisville, Kentucky
Site not named
Frederick, Maryland
Site not named
Moorestown, New Jersey
Site not named
Menlius, New York
Site not named
New York, New York
Site not named
Williamsville, New York
Site not named
Salem, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Mogadore, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Bristol, Tennessee
Site not named
Chattanooga, Tennessee
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.